白细胞介素-22通过多靶点改善中性粒细胞驱动的非酒精性脂肪性肝炎
本研究探讨肝内CXCL1过表达能否驱动高脂饮食小鼠从单纯脂肪变性进展为非酒精性脂肪性肝炎(NASH),并评估IL-22的治疗潜力。结果显示CXCL1过表达通过中性粒细胞浸润、氧化应激和应激激酶激活促进NASH进展,而IL-22通过诱导金属硫蛋白阻断氧化应激并抑制肝细胞来源的线粒体DNA富集细胞外囊泡的促炎功能,从而改善NASH。
要点
- 肝内CXCL1过表达足以驱动高脂饮食小鼠从脂肪变性进展为NASH。
- IL-22通过诱导金属硫蛋白阻断氧化应激及相关应激激酶,改善小鼠NASH。
- IL-22还抑制肝细胞来源的线粒体DNA富集细胞外囊泡的促炎功能,减轻肝脏炎症。
核心结论
- 肝内CXCL1过表达通过中性粒细胞来源活性氧和应激激酶激活驱动高脂饮食小鼠从脂肪变性进展为NASH。
- IL-22通过诱导金属硫蛋白阻断氧化应激及其相关应激激酶,并抑制肝细胞来源的线粒体DNA富集细胞外囊泡的促炎功能,从而改善NASH。
研究设计与样本
- 研究在高脂饮食喂养的小鼠中过表达Cxcl1以诱导NASH,并测试IL-22的治疗效果。
- 使用髓系细胞特异性Ncf1/p47phox基因缺失小鼠验证中性粒细胞氧化爆发在CXCL1诱导NASH中的作用。
- 另在甲硫氨酸-胆碱缺乏饮食诱导的NASH小鼠模型中验证IL-22的疗效。
主要发现
- 肝内Cxcl1过表达单独即可促进高脂饮食小鼠从脂肪变性进展为NASH,伴随中性粒细胞浸润、氧化应激和应激激酶(如ASK1和p38 MAPK)激活。
- 髓系细胞特异性缺失Ncf1/p47phox基因显著减少CXCL1诱导的高脂饮食小鼠NASH和应激激酶激活。
- IL-22治疗改善CXCL1/高脂饮食诱导的NASH及甲硫氨酸-胆碱缺乏饮食诱导的NASH。
- IL-22通过诱导金属硫蛋白阻断肝脏氧化应激及其相关应激激酶。
- IL-22虽不靶向免疫细胞,但可减弱肝细胞来源的线粒体DNA富集细胞外囊泡的促炎功能,从而抑制NASH中的肝脏炎症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease encompasses a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. At present, how simple steatosis progresses to NASH remains obscure and effective pharmacological therapies are lacking. Hepatic expression of C-X-C motif chemokine ligand 1 (CXCL1), a key chemokine for neutrophil infiltration (a hallmark of NASH), is highly elevated in NASH patients but not in fatty livers in obese individuals or in high-fat diet (HFD)-fed mice. The aim of this study was to test whether overexpression of CXCL1 itself in the liver can induce NASH in HFD-fed mice and to test the therapeutic potential of IL-22 in this new NASH model. APPROACH AND RESULTS: Overexpression of Cxcl1 in the liver alone promotes steatosis-to-NASH progression in HFD-fed mice by inducing neutrophil infiltration, oxidative stress, and stress kinase (such as apoptosis signal-regulating kinase 1 and p38 mitogen-activated protein kinase) activation. Myeloid cell-specific deletion of the neutrophil cytosolic factor 1 (Ncf1)/p47phox gene, which encodes a component of the NADPH oxidase 2 complex that mediates neutrophil oxidative burst, markedly reduced CXCL1-induced NASH and stress kinase activation in HFD-fed mice. Treatment with interleukin (IL)-22, a cytokine with multiple targets, ameliorated CXCL1/HFD-induced NASH or methionine-choline deficient diet-induced NASH in mice. Mechanistically, IL-22 blocked hepatic oxidative stress and its associated stress kinases via the induction of metallothionein, one of the most potent antioxidant proteins. Moreover, although it does not target immune cells, IL-22 treatment attenuated the inflammatory functions of hepatocyte-derived, mitochondrial DNA-enriched extracellular vesicles, thereby suppressing liver inflammation in NASH. CONCLUSIONS: Hepatic overexpression of CXCL1 is sufficient to drive steatosis-to-NASH progression in HFD-fed mice through neutrophil-derived reactive oxygen species and activation of stress kinases, which can be reversed by IL-22 treatment via the induction of metallothionein.
引用
- Hwang S, He Y, Xiang X, et al. Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets. Hepatology. 2020. PMID: 31705800. doi:10.1002/hep.31031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。